Related references
Note: Only part of the references are listed.High programmed cell death 1 ligand-1 expression: association with CD8+T-cell infiltration and poor prognosis in human medulloblastoma
Daiki Murata et al.
JOURNAL OF NEUROSURGERY (2018)
PD-L1 expression and prognostic impact in glioblastoma
Edjah K. Nduom et al.
NEURO-ONCOLOGY (2016)
Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients
Rin Ogiya et al.
CANCER SCIENCE (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The prognostic value of PD-L1 expression for non-small cell lung cancer patients: A meta-analysis
A. Wang et al.
EJSO (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Multi-platform profiling of over 2000 sarcomas: Identification of biomarkers and novel therapeutic targets
Sujana Movva et al.
ONCOTARGET (2015)
Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma
Yong Feng et al.
ONCOTARGET (2015)
Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma
Anna Sophie Berghoff et al.
NEURO-ONCOLOGY (2015)
Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072
B. Kasper et al.
ANNALS OF ONCOLOGY (2014)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
Programmed death ligand-1 expression in non-small cell lung cancer
Vamsidhar Velcheti et al.
LABORATORY INVESTIGATION (2014)
Successful use of pazopanib for treatment of refractory metastatic hemangiopericytoma
Su Jin Lee et al.
CLINICAL SARCOMA RESEARCH (2014)
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
S. F. Slovin et al.
ANNALS OF ONCOLOGY (2013)
Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors
Juliann Chmielecki et al.
NATURE GENETICS (2013)
Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing
Dan R. Robinson et al.
NATURE GENETICS (2013)
PD-1 as a potential target in cancer therapy
David F. McDermott et al.
CANCER MEDICINE (2013)
Solitary Fibrous Tumors and Hemangiopericytomas of the Meninges: Overlapping Pathological Features and Common Prognostic Factors Suggest the Same Spectrum of Tumors
Corinne Bouvier et al.
BRAIN PATHOLOGY (2012)
B7-H1, Which Represses EBV-Immortalized B Cell Killing by Autologous T and NK Cells, Is Oppositely Regulated by c-Myc and EBV Latency III Program at Both mRNA and Secretory Lysosome Levels
Stephanie Durand-Panteix et al.
JOURNAL OF IMMUNOLOGY (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Tumor Cell Expression of Programmed Cell Death-1 Ligand 1 Is a Prognostic Factor for Malignant Melanoma
Ryosuke Hino et al.
CANCER (2010)
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)
Stefan Sleijfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Gamma interferon-mediated superinduction of B7-H1 in PTEN-deficient glioblastoma: a paradoxical mechanism of immune evasion
Seunggu J. Han et al.
NEUROREPORT (2009)
CTLA-4 control over Foxp3+ regulatory T cell function
Kajsa Wing et al.
SCIENCE (2008)
Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers
Juro Nakanishi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer
Junzo Hamanishi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance
Changping Wu et al.
ACTA HISTOCHEMICA (2006)
Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer
Y Ohigashi et al.
CLINICAL CANCER RESEARCH (2005)
PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells
Y Iwai et al.
INTERNATIONAL IMMUNOLOGY (2005)
B7-h1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression
J Konishi et al.
CLINICAL CANCER RESEARCH (2004)
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target
RH Thompson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Y Iwai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Share Paper
